CureVac N.V. (Nasdaq: CVAC)

	Start	2020-08-10 existent
	Predecessor	CureVac AG
	Industry	mRNA technology
	Industry 2	mRNA-based drug
	Person	Haas, Franz-Werner (CureVac 202008– CEO joined 201206 as COO before Sygnis + Lion BIoscience)
	Person 2	Hoerr, Ingmar (CureVac 201806– Chairman of Supervisory Board before 2000–201806 CEO + Co-Founder)

	Region	Netherlands_oo
	Country	Netherlands
	City	n. a.
		Address record changed: 2020-08-12

Basic data	Employees	n. a.


		Record changed: 2020-10-13

Picture [iito] Plain Stupid Simple 650x80px

More documents for CureVac N.V. (Nasdaq: CVAC)

[1] Kaleido Biosciences, Inc.. (10/1/20). "Press Release: Kaleido Biosciences Appoints Daniel Menichella as President and Chief Executive Officer". Lexington, MA....
[2] CureVac N.V.. (9/29/20). "Press Release: CureVac Initiates Phase 2a Clinical Trial of COVID-19 Vaccine Candidate. Study Conducted in Peru and Panama". Tübingen & Boston, MA....
[3] CureVac B.V.. (8/18/20). "Press Release: CureVac Announces Closing of Initial Public Offering". Tübingen & Boston, MA....
[4] CureVac B.V.. (8/14/20). "Press Release: CureVac Announces Pricing of Initial Public Offering". Tübingen & Boston, MA....
[5] CureVac B.V.. (8/10/20). "Press Release: CureVac Announces Proposed Initial Public Offering of Common Shares". Tübingen....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]